Long-term results of a multimodal intensification regimen for previously untreated advanced resectable squamous cell cancer of the oral cavity, oropharynx, or hypopharynx

Laryngoscope

Volumn 116, Issue 4, 2006, Pages 607-612

  Ozer, Enver ^a,b   Grecula, John C ^a   Agrawal, Amit ^a   Rhoades, Chris A ^a   Young, Donn C ^a   Schuller, David E ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Chemoradiotherapy; Chemotherapy; Head and neck carcinoma; Radiotherapy

Indexed keywords

CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CENTER; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HYPOPHARYNX CARCINOMA; INTRAOPERATIVE RADIOTHERAPY; MALE; MOUTH CARCINOMA; MULTIMODALITY CANCER THERAPY; OROPHARYNX CARCINOMA; PATIENT COMPLIANCE; PEROPERATIVE CARE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; ADJUVANT THERAPY; EAR NOSE THROAT SURGERY; FOLLOW UP; HYPOPHARYNX TUMOR; METHODOLOGY; MIDDLE AGED; MOUTH TUMOR; OROPHARYNX TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOPHARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; OROPHARYNGEAL NEOPLASMS; OTORHINOLARYNGOLOGIC SURGICAL PROCEDURES; PACLITAXEL; PATIENT COMPLIANCE; RADIOTHERAPY, ADJUVANT; TIME FACTORS; TREATMENT OUTCOME;

EID: 33645926336     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlg.0000208340.42071.f9     Document Type: Article

References (19)

1. Landis S, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:12-13.
2. Laramore GE, Scott CB, Al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 1992;23:705-713.
3. Schuller DE, King GW, Smith RE, Wilson HE, James AD, Batley F. Combination therapy protocol for stage III and stage IV carcinoma of the oral cavity, oropharynx, and hypopharynx. Laryngoscope 1980;90:1263-1727.
4. Wheeler RH. Chemotherapy of patients with recurrent head and neck cancer. In: Jacobs C, ed. Carcinomas of the Head and Neck: Evaluation and Management. Boston: Kluwer Academic Publishers; 1990:171-193.
5. Schuller DE. Do otolaryngologist-head and neck surgeons and/or chemotherapy have a role in the treatment of head and neck cancer? Arch Otolaryngol Head Neck Surg 1991;117:498-501.
6. Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 1988;98:1205-1211.
7. Kish J, Ensley J, Benedetti D, Schuller D, Al-Sarraf M. Post-operative adjuvant treatment of advanced head and neck cancer: Wayne State University experience and Southwest Oncology Group Feasibility Trial [Abstract]. Am Soc Clin Oncol 1993;12:285.
8. Wolf G, Vikram B, Jacobs C, et al. Adjuvant chemotherapy for advanced head and neck squamous cell carcinoma: final report of the Head and Neck Contracts Program. Cancer 1987;60:301-311.
9. Fu K. Combined-modality therapy for head and neck cancer. Oncology 1997;11:1781-1796.
10. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099 (SWOG 8892, RTOG 8817, ECOG 2388). J Clin Oncol 1998;16:1310-1317.
11. Al-Sarraf M, Pajak TF, Byhardt RW, Beitler JJ, Salter MM, Cooper JS. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 1997;27:777-782.
12. Hanna E, Alexiou M, Morgan J, et al. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations. Arch Otolaryngol Head Neck Surg 2004;130:861-867.
13. Al-Sarraf M, LeBlanc M, Giri PG, et al. Superiority of five year survival with chemoradiotherapy versus radiotherapy in patients with locally advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099: final report [Abstract #905]. Proc ASCO 2001;20:2272.
14. Schuller DE, Grecula JC, Gahbauer RA, et al. Intensified regimen for advanced head and neck squamous cell carcinomas. Arch Otolaryngol Head Neck Surg 1997;123:139-144.
15. Grecula JC, Schuller DE, Rhoades CA, et al. Intensification regimen 2 for advanced head and neck squamous cell carcinomas. Arch Otolaryngol Head Neck Surg 1999;125:1313-1318.
16. Grecula JC, Smith RE, Rhoades CA, et al. Phase II trial: induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of the head and neck. Cancer 2000;89:2587-2596.
17. Schuller DE, Laramore G, Al-Sarraf M, Jacobs J, Pajak TF. Combined therapy for resectable head and neck cancer: a phase 3 Intergroup Study. Arch Otolaryngol Head Neck Surg 1989;115:364-368.
18. Schuller DE, Grecula JC, Agrawal A, et al. Multimodal intensification therapy for previously untreated advanced respectable squamous cell carcinoma of the oral cavity, oropharynx, or hypopharynx. Cancer 2002;94:3169-3178.
19. Malone JP, Stephens JA, Grecula JC, Rhoades CA, Ghaheri BA, Schuller DE. Disease control, survival, and functional outcome after multimodal treatment for advanced-stage tongue base cancer. Head Neck 2004;26:561-572.